Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88285 | 0.98 | TSHR (0.81) | TSHRCYP3A4MAPK1TP53ALDH1A1 | |
| SCHEMBL12095195 | 0.98 | TSHR (0.81) | TSHRCYP3A4MAPK1TP53ALDH1A1 | |
| SCHEMBL7459965 | 0.97 | ALDH1A1 (0.81) | TSHRCYP3A4MAPK1TP53ALDH1A1 | |
| SCHEMBL1005991 | 0.97 | ALDH1A1 (0.81) | TSHRCYP3A4MAPK1TP53ALDH1A1 | |
| SCHEMBL1923016 | 0.97 | ALDH1A1 (0.81) | TSHRCYP3A4MAPK1TP53ALDH1A1 | |
| SCHEMBL4731100 | 0.97 | ALDH1A1 (0.81) | TSHRCYP3A4MAPK1TP53ALDH1A1 | |
| SCHEMBL411474 | 0.97 | ALDH1A1 (0.81) | TSHRCYP3A4MAPK1TP53ALDH1A1 | |
| SCHEMBL2801630 | 0.97 | ALDH1A1 (0.81) | TSHRCYP3A4MAPK1TP53ALDH1A1 | |
| 2-Hydroxybenzoic Acid Hexyl Ester SCHEMBL113059 | 0.97 | ALDH1A1 (0.81) | TSHRCYP3A4MAPK1TP53ALDH1A1 | |
| SCHEMBL8927962 | 0.97 | ALDH1A1 (0.81) | TSHRCYP3A4MAPK1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281926-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | GIMI RAYOMAND H | 2006-12-14 | — | — | US | claimed |
| US-7576234-B2 | Michael-type addition of a nucleophile to a dialkyl 2-methylidenylpropan-1,3-dioate and the conversion of a ester moiety into an amino moiety; S)-2-methylcysteine; desferrithiocin | GENZYME CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1529037-B1 | SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | GENZYME CORP (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20060281926-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | GIMI RAYOMAND H | 2006-12-14 | — | — | US | disclosed |
| US-7115769-B2 | Synthesis of 2-alkylcysteine via phase transfer catalysis | GENZYME CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060167267-A1 | Synthesis of 2-alkyl amino acids | CHORGHADE MUKUND S | 2006-07-27 | — | — | US | disclosed |
| US-7002036-B2 | Synthesis of 2-alkyl amino acids | GENZYME CORPORATION (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1529037-A2 | SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | Genzyme Corporation (US) | 2005-05-11 | — | — | EP | disclosed |
| US-6878828-B2 | Synthesis of 2-alkylcysteine via substituted thiazoline ester | GENZYME CORPORATION (US) | 2005-04-12 | — | — | US | disclosed |
| US-6861532-B2 | Synthesis of 2-alkylcysteine | GENZYME CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-6794515-B2 | CONDENSING CYSTEINE WITH CABOCYCLIC NITRILES TO FORM 2-ARYLTHIAZOLINE-4-CARBOXYLIC ACID, THEN AMIDATION, ALKYLATION, HYDROLYZING AND OPTIONALLY PURIFYING TO FORM 2-METHYLCYSTEINE | GENZYME CORPORATION | 2004-09-21 | — | — | US | disclosed |
| US-20040024224-A1 | Synthesis of 2-alkyl amino acids | GENZYME CORPORATION (US) | 2004-02-05 | — | — | US | disclosed |
| US-20030236435-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline ester | GENZYME CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-20030236434-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline amide | GENZYME CORPORATION (US) | 2003-12-25 | — | — | US | disclosed |
| US-20030236404-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | GENZYME CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-20030229231-A1 | Synthesis of 2-alkylcysteine | GENZYME CORPORATION | 2003-12-11 | — | — | US | disclosed |
| WO-2003097622-A2 | SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | GENZYME CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236404-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | DIMT1, ICMT, CNDP2 | TSHR 1787/4885CYP3A4 2320/4885MAPK1 4035/4885 |
| US-20030236435-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline ester | FTH1, TFRC, CNDP2 | TSHR 178/4885CYP3A4 2981/4885MAPK1 4509/4885 |
| US-20030229231-A1 | Synthesis of 2-alkylcysteine | FTH1, CISD2, CNDP2 | TSHR 499/4885CYP3A4 3118/4885MAPK1 4319/4885 |
| US-20040024224-A1 | Synthesis of 2-alkyl amino acids | PTMS, DNPEP, CNDP2 | TSHR 728/4885CYP3A4 3108/4885MAPK1 3646/4885 |
| US-20030236434-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline amide | CNDP2, FTH1, PTMS | TSHR 485/4885CYP3A4 3961/4885MAPK1 4308/4885 |
| US-20060167267-A1 | Synthesis of 2-alkyl amino acids | PTMS, DNPEP, CNDP2 | TSHR 728/4885CYP3A4 3108/4885MAPK1 3646/4885 |
| US-20060281926-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | DIMT1, ICMT, CNDP2 | TSHR 1787/4885CYP3A4 2320/4885MAPK1 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.